Pharma & Biotech - Page 6

The shift toward home-administered pharmaceutical therapies is accelerating, prompting organisations to fundamentally rethink how they guide patients through complex clinical transitions. Healthcare companies are under growing pressure to ensure patients feel equipped

Bayer HealthCare Pharmaceuticals has secured expanded FDA accelerated approval for sevabertinib, sold as Hyrnuo, targeting previously untreated HER2-mutated non-small cell lung cancer patients. The U.S. Food and Drug Administration granted the expanded

The pharmaceutical industry’s shift to 12-digit National Drug Codes carries its greatest risk not inside individual systems, but at the handoffs between organisations. That is the central warning from Liberty Dewey, manager

Pharmaceutical giant Merck & Co. (MRK) has filed notice with New Jersey state officials confirming 54 additional layoffs at its Rahway location. The filing was made in September with the New Jersey

President Donald Trump announced nine new most-favoured-nation agreements with pharmaceutical manufacturers on 31 August, expanding the programme significantly. The latest additions bring the total number of participating companies to 26, which the

Novo Nordisk has reported a significant phase 3 trial result for Wegovy in younger children, with two in five participants no longer classified as having obesity after 68 weeks of treatment. The

Gregg Gorniak, vice president of manufacturer operations and data services and secure supply chain lead at Cencora, argues that DSCSA compliance investments only create value when trading partners agree on what “value”

Sandoz is positioning itself for long-term growth by making significant investments in its biosimilar capabilities over the coming years. The Swiss generics and biosimilars giant sees a major commercial opportunity on the

Pharmaceutical cargo has historically represented the gold standard of supply chain security, with the industry investing heavily in layered protections and advanced technology. The sector has long recognised its lower risk tolerance

Amgen has announced landmark results from its Phase 3 DeLLphi-305 study, marking a significant breakthrough in the treatment of small cell lung cancer. The trial met its primary endpoint at a pre-specified